Ilaprazole, a new proton pump inhibitor, is primarily metabolized to ilaprazole sulfone by CYP3A4 and 3A5

References

• Andersson T, Holmberg J, Röhss K, Walan A. (1998). Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole. Br J Clin Pharmacol 45:369–375.
   PubMed Web of Science ®Google Scholar
• Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE, Chenery RJ. (1995). Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25:261–270.
   PubMed Web of Science ®Google Scholar
• Bates ER, Lau WC, Angiolillo DJ. (2011). Clopidogrel-drug interactions. J Am Coll Cardiol 57:1251–1263.
   PubMed Web of Science ®Google Scholar
• DellaGreca M, Iesce MR, Previtera L, Rubino M, Temussi F, Brigante M. (2006). Degradation of lansoprazole and omeprazole in the aquatic environment. Chemosphere 63:1087–1093.
   PubMed Web of Science ®Google Scholar
• Gebeyehu E, Engidawork E, Bijnsdorp A, Aminy A, Diczfalusy U, Aklillu E. (2011). Sex and CYP3A5 genotype influence total CYP3A activity: High CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians. Pharmacogenomics J 11:130–137.
   PubMed Web of Science ®Google Scholar
• Grothusen A, Hardt J, Bräutigam L, Lang D, Böcker R. (1996). A convenient method to discriminate between cytochrome P450 enzymes and flavin-containing monooxygenases in human liver microsomes. Arch Toxicol 71:64–71.
   PubMed Web of Science ®Google Scholar
• Katsuki H, Hamada A, Nakamura C, Arimori K, Nakano M. (2001). Role of CYP3A4 and CYP2C19 in the stereoselective metabolism of lansoprazole by human liver microsomes. Eur J Clin Pharmacol 57:709–715.
   PubMed Web of Science ®Google Scholar
• Kim KA, Kim MJ, Park JY, Shon JH, Yoon YR, Lee SS, Liu KH, Chun JH, Hyun MH, Shin JG. (2003). Stereoselective metabolism of lansoprazole by human liver cytochrome P450 enzymes. Drug Metab Dispos 31:1227–1234.
   PubMed Web of Science ®Google Scholar
• Kim KB, Seo KA, Yoon YJ, Bae MA, Cheon HG, Shin JG, Liu KH. (2008). In vitro metabolism of a novel PPAR gamma agonist, KR-62980, and its stereoisomer, KR-63198, in human liver microsomes and by recombinant cytochrome P450s. Xenobiotica 38:1165–1176.
   PubMed Web of Science ®Google Scholar
• Kim MJ, Kim H, Cha IJ, Park JS, Shon JH, Liu KH, Shin JG. (2005). High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 19:2651–2658.
   PubMed Web of Science ®Google Scholar
• Kita T, Sakaeda T, Baba T, Aoyama N, Kakumoto M, Kurimoto Y, Kawahara Y, Okamura N, Kirita S, Kasuga M, Okumura K. (2003). Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors. Biol Pharm Bull 26:386–390.
   PubMed Web of Science ®Google Scholar
• Klotz U. (2006). Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: A review of a special problem. Int J Clin Pharmacol Ther 44:297–302.
   PubMed Web of Science ®Google Scholar
• Klotz U, Schwab M, Treiber G. (2004). CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol 95:2–8.
   PubMed Web of Science ®Google Scholar
• Krusekopf S, Roots I, Kleeberg U. (2003). Differential drug-induced mRNA expression of human CYP3A4 compared to CYP3A5, CYP3A7 and CYP3A43. Eur J Pharmacol 466:7–12.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang W, Guo D, Zhou G, Zhou H, Xiao Z. (2008). Pharmacokinetics of the new proton pump inhibitor ilaprazole in Chinese healthy subjects in relation to CYP3A5 and CYP2C19 genotypes. Clin Chim Acta 391:60–67.
   PubMed Web of Science ®Google Scholar
• Myung SW, Min HK, Jin C, Kim M, Lee SM, Chung GJ, Park SJ, Kim DY, Cho HW. (1999). Identification of IY81149 and its metabolites in the rat plasma using the on-line HPLC/ESI mass spectrometry. Arch Pharm Res 22:189–193.
   PubMed Web of Science ®Google Scholar
• Nace CG, Genter MB, Sayre LM, Crofton KM. (1997). Effect of methimazole, an FMO substrate and competitive inhibitor, on the neurotoxicity of 3,3′-iminodipropionitrile in male rats. Fundam Appl Toxicol 37:131–140.
   PubMedGoogle Scholar
• Pichard L, Curi-Pedrosa R, Bonfils C, Jacqz-Aigrain E, Domergue J, Joyeux H, Cosme J, Guengerich FP, Maurel P. (1995). Oxidative metabolism of lansoprazole by human liver cytochromes P450. Mol Pharmacol 47:410–418.
   PubMed Web of Science ®Google Scholar
• Sagar M, Bertilsson L, Stridsberg M, Kjellin A, Mârdh S, Seensalu R. (2000). Omeprazole and CYP2C19 polymorphism: Effects of long-term treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders. Aliment Pharmacol Ther 14:1495–1502.
   PubMed Web of Science ®Google Scholar
• Sibbing D, Morath T, Stegherr J, Braun S, Vogt W, Hadamitzky M, Schömig A, Kastrati A, von Beckerath N. (2009). Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 101:714–719.
   PubMed Web of Science ®Google Scholar
• Stresser DM, Broudy MI, Ho T, Cargill CE, Blanchard AP, Sharma R, Dandeneau AA, Goodwin JJ, Turner SD, Erve JC, Patten CJ, Dehal SS, Crespi CL. (2004). Highly selective inhibition of human CYP3Aa in vitro by azamulin and evidence that inhibition is irreversible. Drug Metab Dispos 32:105–112.
   PubMed Web of Science ®Google Scholar
• Sugimoto M, Furuta T, Shirai N, Kajimura M, Hishida A, Sakurai M, Ohashi K, Ishizaki T. (2004). Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther 76:290–301.
   PubMed Web of Science ®Google Scholar
• Zhou G, Shi S, Zhang W, Tan Z, Chen Y, Guo D, Zhou H, Hu H, Tan J. (2010). Identification of ilaprazole metabolites in human urine by HPLC-ESI-MS/MS and HPLC-NMR experiments. Biomed Chromatogr 24:1130–1135.
   PubMed Web of Science ®Google Scholar
• Zhou G, Tan ZR, Zhang W, Ou-Yang DS, Chen Y, Guo D, Liu YZ, Fan L, Deng HW. (2009). An improved LC-MS/MS method for quantitative determination of ilaprazole and its metabolites in human plasma and its application to a pharmacokinetic study. Acta Pharmacol Sin 30:1330–1336.
   PubMed Web of Science ®Google Scholar